Advancing knowledge for the clinical and public health response to the 2019-nCoV epidemic |
Call ID:H2020-SC1-PHE-CORONAVIRUS-2020
Termin:
30.06.2021
Fördergeber:
EU - HORIZONT 2020
Specific Challenge:
On 31 December 2019, the local authorities of Wuhan, Hubei province, China, reported a cluster of pneumonia cases of unknown origin. On 9 January 2020, the China Centre for Disease Control reported a novel Coronavirus (2019-nCoV) to be the causative agent.
As of 30 January 2020, 7824 laboratory-confirmed cases of 2019-nCoV have been reported including 170 deaths[1]. The disease has already spread to 19 countries outside China, with new cases continuing to emerge daily.
Recalling the SARS-CoV epidemic in 2003 with over 8000 cases reported (10% case fatality), it is crucial to rapidly gain a better understanding of the newly identified virus, especially in relation to potential clinical and public health measures that can be put to immediate use to improve patients health and/or contain the spread of 2019-nCoV.
Scope:
Proposals submitted under this expression of interest are expected to advance the knowledge on 2019-nCoV and its impact on infected persons, with the aim of contributing to an efficient patient management and/or public health preparedness and response. Proposals must be timely, with rapid activation, to enable early and valuable outcomes to be established. For increased impact, proposals may wish to build on promising avenues from previous or ongoing research.
Considering that this is a newly identified virus, the scope of this expression of interest remains broad and may include topics such as:
Development of therapeutics, including monoclonal antibodies. As relevant, evidence of regulatory and ethics approvals for the investigational products included in the study(ies) must be presented.
Development of point of care diagnostics, ensuring rapid evaluation of candidates based on existing technologies, to allow for fast case detection and surveillance.
Clinical and epidemiological studies, to provide data on epidemiological characteristics such as viral genotype and pathogenicity; clinical information on host susceptibility and host immune responses; risk factors for severe disease; routes of transmission and their relative importance; identification of the animal reservoir; etc.
Social sciences research, to provide urgently needed answers to social dynamics of the outbreak and the related public health response.
Call:
https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/sc1-phe-coronavirus-2020;freeTextSearchKeyword=;typeCodes=1;statusCodes=31094502;programCode=H2020;programDivisionCode=null;focusAreaCode=null;crossCuttingPriorityCode=null;callCode=Default;sortQuery=openingDate;orderBy=desc;onlyTenders=false;topicListKey=topicSearchTablePageState
On 31 December 2019, the local authorities of Wuhan, Hubei province, China, reported a cluster of pneumonia cases of unknown origin. On 9 January 2020, the China Centre for Disease Control reported a novel Coronavirus (2019-nCoV) to be the causative agent.
As of 30 January 2020, 7824 laboratory-confirmed cases of 2019-nCoV have been reported including 170 deaths[1]. The disease has already spread to 19 countries outside China, with new cases continuing to emerge daily.
Recalling the SARS-CoV epidemic in 2003 with over 8000 cases reported (10% case fatality), it is crucial to rapidly gain a better understanding of the newly identified virus, especially in relation to potential clinical and public health measures that can be put to immediate use to improve patients health and/or contain the spread of 2019-nCoV.
Scope:
Proposals submitted under this expression of interest are expected to advance the knowledge on 2019-nCoV and its impact on infected persons, with the aim of contributing to an efficient patient management and/or public health preparedness and response. Proposals must be timely, with rapid activation, to enable early and valuable outcomes to be established. For increased impact, proposals may wish to build on promising avenues from previous or ongoing research.
Considering that this is a newly identified virus, the scope of this expression of interest remains broad and may include topics such as:
Development of therapeutics, including monoclonal antibodies. As relevant, evidence of regulatory and ethics approvals for the investigational products included in the study(ies) must be presented.
Development of point of care diagnostics, ensuring rapid evaluation of candidates based on existing technologies, to allow for fast case detection and surveillance.
Clinical and epidemiological studies, to provide data on epidemiological characteristics such as viral genotype and pathogenicity; clinical information on host susceptibility and host immune responses; risk factors for severe disease; routes of transmission and their relative importance; identification of the animal reservoir; etc.
Social sciences research, to provide urgently needed answers to social dynamics of the outbreak and the related public health response.
Call:
https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/sc1-phe-coronavirus-2020;freeTextSearchKeyword=;typeCodes=1;statusCodes=31094502;programCode=H2020;programDivisionCode=null;focusAreaCode=null;crossCuttingPriorityCode=null;callCode=Default;sortQuery=openingDate;orderBy=desc;onlyTenders=false;topicListKey=topicSearchTablePageState